Tuberculosis control in China

Lin, H.H., Wang, L., Zhang, H., Ruan, Y., Chin, D.P. and Dye, C., 2015. Tuberculosis control in China: use of modelling to develop targets and policies. Bulletin of the World Health Organization, 93, pp.790-798.

  • MDR tuberculosis often results from person-to-person transmission, not just unsuccessful hospital treatments.
  • China likely cannot meet the current global targets for tuberculosis control.
  • By 2010, China achieved older global targets of halving tuberculosis prevalence and mortality between 1990 and 2015.
  • This success was driven by shifting tuberculosis treatment from hospitals to Chinese CDC public health centers.
  • Future reductions in tuberculosis incidence and mortality are expected to be much slower.
  • The most optimistic scenario predicts only an 18% reduction in incidence and a 28% reduction in mortality between 2015 and 2025.
  • Current targets will not be met by 2025 with passive surveillance alone.
  • Active and enhanced surveillance may accelerate declines in tuberculosis but with unclear individual and community benefits.
  • The global tuberculosis targets for 2035 (90% reduction in incidence, 95% reduction in mortality) appear even less attainable.
  • Achieving the 2035 targets may require a new vaccine or prophylactic treatment for latent infections.
  • Reducing MDR tuberculosis prevalence could be achieved by improving treatment of drug-susceptible tuberculosis or enhancing MDR tuberculosis diagnosis and treatment.
  • A combination of both interventions could lead to the greatest impact, with an estimated 75% decline in MDR tuberculosis prevalence over the decade starting in 2015. 

    • Comments

    Post a Comment

    Popular posts from this blog

    Nutritional status in patients with TB and DM

    Patel, D.G., Baral, T., Kurian, S.J., Malakapogu, P., Saravu, K. and Miraj, S.S., 2024. Nutritional status in patients with tuberculosis and diabetes mellitus: A comparative observational study.  Journal of Clinical Tuberculosis and Other Mycobacterial Diseases ,  35 , p.100428. Cardiovascular disease prevalence was highest in the DM group, followed by the TB-DM group. Anaemia was more prevalent in the TB-DM group. Smoking and alcohol use were most common in the TB group, followed by the TB-DM group. See also: TB and kidney function impairment In the TB-DM group, HbA1c levels indicated poor diabetic control (10.47%), higher than in the DM group (8.17%). FBS was also above normal in the TB-DM group, followed by the DM group. Although there were no significant differences in nutritional parameters like albumin, globulin, and total proteins, vitamin B12 levels were highest in the TB-DM group. Notably, 95.83% of patients in the TB-DM group had HbA1c > 6.5, with similarly high FBS and RB
    Read more

    Scientific advances and the end of tuberculosis

    Reid, M., Agbassi, Y.J.P., Arinaminpathy, N., Bercasio, A., Bhargava, A., Bhargava, M., Bloom, A., Cattamanchi, A., Chaisson, R., Chin, D. and Churchyard, G., 2023. Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.  The Lancet ,  402 (10411), pp.1473-1498. Progress toward ending tuberculosis varies greatly across countries, with some achieving substantial improvements and others making minimal progress. Key challenges include frail health systems, underinvestment, and reliance on one-size-fits-all approaches. Insufficient case finding and diagnosis remain the most significant issues in high-burden countries, where only 38% of all tuberculosis cases were tested with WHO-recommended rapid molecular diagnostics in 2021. Two-thirds of tuberculosis deaths occurred in just eight countries, with over half of these in India, Indonesia, and Nigeria. Despite these challenges, some sub-Saharan African countries have seen improvements in tubercul
    Read more

    Impact of diabetes on tuberculosis and MDRTB susceptibility

    There is a significant association between diabetes mellitus (DM) and multidrug-resistant tuberculosis (MDR-TB). TB patients without DM have a lower risk of developing MDR-TB compared to those with DM. Factors contributing to MDR-TB emergence in TB patients with DM include: Impaired immune function Altered microbial genomics Uncontrolled glucose levels, increasing susceptibility to MDR-TB Compromised phagocytic activity and reduced chemotactic response Increased oxidative species and microbe proliferation Altered drug disposition Higher likelihood of non-adherence to treatment TB patients with DM also experience higher treatment failure rates compared to those without DM. Most information on these associations is based on self-reported data or patient health records, which may introduce assessment errors Rehman Au, Khattak M, Mushtaq U, Latif M, Ahmad I, Rasool MF, Shakeel S, Hayat K, Hussain R, Alhazmi GA, Alshomrani AO, Alalawi MI, Alghamdi S, Imam MT, Almarzoky Abuhussain SS, Khayya
    Read more